Animal Gastroesophageal Reflux Disease Market Size & Growth Forecast 2027–2036, By Segments (Mode, Route of Administration, Animal, Distribution Channel, Product), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Animal Gastroesophageal Reflux Disease Market size stood at USD 3.9 billion in 2026 and is predicted to grow at a 7.32% CAGR from 2027 to 2036, crossing USD 7.9 billion by 2036. The industry revenue for 2027 is estimated at USD 4.14 billion.
Get more details on this report
Request Free Sample ReportAnimal Gastroesophageal Reflux Disease Market Intelligence Snapshot
Regional Market Dynamics
- North America captured a 45.98% market share in 2026, supported by advanced veterinary infrastructure, high pet ownership, structured diagnosis, and consistent treatment and follow-up care.
- Asia Pacific is forecast to grow at an 8.7% CAGR as rising pet adoption, expanding veterinary services, and greater awareness of digestive health increase demand for diagnosis and targeted treatments.
Segment Momentum
- OTC held a 59.75% share in 2026 as readily accessible treatments support early symptom management, repeat purchases, and quicker buying decisions for common reflux-related conditions in animals.
- Oral administration accounted for 63.44% of the market in 2026 and continues to grow fastest because it offers practical, convenient, and consistent treatment for routine and long-term reflux management in animals.
Market Expansion Drivers
- Rising prevalence of GERD and obesity in companion animals increasing veterinary treatment demand.
- Advancements in veterinary endoscopy and diagnostic imaging improving early GERD detection in pets.
- Growing pet humanization and pet insurance adoption supporting expenditure on gastrointestinal care solutions.
Leading Market Participants
- Prominent players in the animal gastroesophageal reflux disease market include Boehringer Ingelheim International GmbH (Germany), Zoetis Inc. (United States), Merck & Co., Inc. (United States), Ceva Santé Animale (France), Hill's Pet Nutrition, Inc. (United States), Blue Buffalo Co., Ltd. (United States), Elanco Animal Health Incorporated (United States), Virbac S.A. (France).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 3.9 billion
- 2027 Estimated Market Size: USD 4.14 billion.
- Projected Market Size: USD 7.9 billion by 2036
- Growth Forecast: 7.32% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: OTC (Mode) | Oral (Route of Administration) | Companion Animal (Animal) | E-commerce (Distribution Channel) | Treatment (Product)
- Emerging Opportunity Segment: Prescription (Mode) | Oral (Route of Administration) | Companion Animal (Animal) | E-commerce (Distribution Channel) | Diagnostics (Product)
Market Growth Drivers and Industry Trends
Rising prevalence of GERD and obesity in companion animals increasing veterinary treatment demand
Increasing occurrence of gastrointestinal disorders alongside obesity among companion animals is creating a stronger need for veterinary evaluation and treatment, which will propel the animal gastroesophageal reflux disease market growth. Excess body weight can contribute to digestive complications and may intensify symptoms associated with reflux, encouraging pet owners to seek professional care when animals experience vomiting, regurgitation, appetite changes, or related gastrointestinal problems. Greater veterinary awareness of these conditions is also supporting more systematic assessment and management, increasing demand for appropriate medications, dietary interventions, and supportive gastrointestinal care solutions.
Advancements in veterinary endoscopy and diagnostic imaging improving early GERD detection in pets
Technological progress in veterinary diagnostic procedures is enabling practitioners to identify gastrointestinal abnormalities with greater precision, strengthening the animal gastroesophageal reflux disease market. Improved endoscopic techniques provide veterinarians with better visualization of the upper gastrointestinal tract, while diagnostic imaging can support the assessment of structural or functional abnormalities associated with digestive symptoms. Earlier and more accurate identification of reflux-related conditions allows treatment plans to be developed according to individual animal needs and can help distinguish GERD from other causes of vomiting or regurgitation, increasing the use of specialized diagnostic services and therapeutic interventions.
Growing pet humanization and pet insurance adoption supporting expenditure on gastrointestinal care solutions
The increasing treatment of companion animals as family members is encouraging owners to prioritize comprehensive healthcare and seek professional intervention for persistent digestive problems, supporting the animal gastroesophageal reflux disease market demand. Pet humanization is driving greater willingness to invest in veterinary consultations, diagnostic procedures, prescription treatments, and specialized diets rather than relying solely on basic home care. At the same time, broader adoption of pet insurance can reduce the financial burden associated with eligible veterinary services, making advanced gastrointestinal assessment and treatment more accessible to pet owners seeking ongoing care for their animals.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising prevalence of GERD and obesity in companion animals increasing veterinary treatment demand | 2.00% | Moderate | North America, Europe, Asia Pacific | High | Near Term |
| Advancements in veterinary endoscopy and diagnostic imaging improving early GERD detection in pets | 1.80% | Moderate | North America, Asia Pacific | High | Mid Term |
| Growing pet humanization and pet insurance adoption supporting expenditure on gastrointestinal care solutions | 1.50% | Moderate | North America, Europe | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America held the largest share of the animal gastroesophageal reflux disease market, accounting for 45.98% in 2026, supported by advanced veterinary healthcare infrastructure and growing attention to companion animal health. Greater awareness of digestive disorders among pet owners, increased use of veterinary diagnostic services, and improved access to specialized animal healthcare are supporting demand for effective disease management. The region’s established veterinary care systems and emphasis on preventive and therapeutic treatment further reinforce its market position.
Asia Pacific (Fastest-Growing Region)
Asia Pacific represents the fastest-growing region, driven by rising pet ownership, increasing expenditure on animal healthcare, and expanding access to veterinary services. Growing awareness of companion animal wellness is encouraging earlier diagnosis and treatment of gastrointestinal conditions, while improvements in veterinary infrastructure are broadening access to specialized care. Urbanization and changing attitudes toward pets are also increasing demand for higher-quality animal healthcare, creating favorable conditions for market expansion.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Clinical Treatment StandardsGermany emphasizes evidence-based veterinary care and structured treatment approaches for gastrointestinal disorders in companion animals. Veterinary clinics are adopting improved diagnostic protocols while expanding access to specialized digestive health management solutions.
France 🇫🇷
Preventive Pet HealthcareFrance is strengthening preventive veterinary care with greater attention to digestive health in companion animals. Veterinary professionals are combining nutritional guidance with pharmaceutical treatment strategies to support effective gastroesophageal reflux disease management.
Italy 🇮🇹
Integrated Digestive CareItaly's veterinary sector is placing greater emphasis on integrated management of chronic gastrointestinal conditions in pets. Clinics are adopting broader diagnostic assessments and tailored treatment plans to improve animal health and owner satisfaction.
Japan 🇯🇵
Companion Animal WellnessJapan's animal gastroesophageal reflux disease market is supported by high standards of pet healthcare and growing attention to chronic digestive disorders. Veterinary providers are integrating advanced diagnostics with nutritional management to improve long-term treatment outcomes.
South Korea 🇰🇷
Specialty Veterinary ServicesSouth Korea continues expanding specialized veterinary services as awareness of gastrointestinal disorders in companion animals increases. Market participants are focusing on improved diagnosis, targeted therapeutics, and owner education to support comprehensive disease management.
United States 🇺🇸
Advanced Veterinary CareThe U.S. animal gastroesophageal reflux disease market benefits from widespread access to companion animal healthcare and specialized veterinary services. Companies are expanding diagnostic capabilities and therapeutic options as pet owners increasingly seek early intervention for gastrointestinal conditions.
Segment Leadership and Growth Trends
Animal Gastroesophageal Reflux Disease Market Share (%), by Mode, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportMode Segment Analysis: OTC (Largest Segment) vs Prescription (Fastest-Growing Segment)
The OTC segment held the largest share of the animal gastroesophageal reflux disease market at 59.75% in 2026, supported by the accessibility and convenience of non-prescription treatment options for managing gastrointestinal symptoms in animals. Pet owners and animal caregivers often favor readily available therapies for routine or less complex conditions, while veterinarians may also recommend accessible treatments as part of broader symptom-management approaches. Ease of procurement and familiarity with OTC gastrointestinal products reinforce the segment's established position.
Prescription therapies represent the fastest-growing mode segment as more complex gastrointestinal conditions increasingly require targeted veterinary management. Prescription treatments can provide more specialized therapeutic approaches for animals with persistent or clinically significant reflux symptoms, particularly when routine management is insufficient. Greater awareness of veterinary gastrointestinal health and increasing emphasis on professional diagnosis and individualized treatment strategies are supporting adoption of prescription-based care.
Route of Administration Segment Analysis: Oral (Largest & Fastest-Growing Segment)
The oral segment led the animal gastroesophageal reflux disease market in 2026 with a 63.44% share and is also the fastest-growing route of administration. Oral therapies offer practical dosing, ease of administration, and broad suitability for ongoing gastrointestinal treatment, making them convenient for both veterinary professionals and animal caregivers. Their compatibility with commonly used formulations and the growing focus on manageable at-home treatment routines further strengthen demand. Continued development of palatable and easy-to-administer oral formulations is supporting the segment's combined market leadership and growth momentum.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Mode | OTC, Prescription | OTC | Prescription |
| Route of Administration | Oral, Injectable | Oral | Oral |
| Animal | Companion Animal, Livestock Animal | Companion Animal | Companion Animal |
| Distribution Channel | Veterinary Hospitals & Clinics, Retail Pharmacies, E-commerce | E-commerce | E-commerce |
| Product | Diagnostics, Treatment, Others | Treatment | Diagnostics |
Competitive Landscape and Market Positioning
Leading companies in the animal gastroesophageal reflux disease market:
1. Boehringer Ingelheim International GmbH (Germany)
2. Zoetis Inc. (United States)
3. Merck & Co. Inc. (United States)
4. Ceva Santé Animale (France)
5. Hill's Pet Nutrition Inc. (United States)
6. Blue Buffalo Co. Ltd. (United States)
7. Elanco Animal Health Incorporated (United States)
8. Virbac S.A. (France)
The animal gastroesophageal reflux disease market is witnessing growing attention toward specialized therapeutic development aimed at improving digestive health in companion animals. Industry participants are focusing on expanding treatment portfolios through acquisition-driven expansion and research initiatives targeting more effective formulations. The market is further shaped by rising awareness among pet owners regarding long-term gastrointestinal care and preventive veterinary solutions.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim International GmbH (Germany) | |||||||
| Zoetis Inc. (United States) | |||||||
| Merck & Co. Inc. (United States) | |||||||
| Ceva Santé Animale (France) | |||||||
| Hill's Pet Nutrition Inc. (United States) | |||||||
| Blue Buffalo Co. Ltd. (United States) | |||||||
| Elanco Animal Health Incorporated (United States) | |||||||
| Virbac S.A. (France). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Esaote North America Inc. | May-24 | The company launched the "MyLab FOX," a versatile and portable veterinary ultrasound system. Designed for high-performance abdominal and cardiac imaging, the system aids in the precise diagnosis of gastrointestinal and esophageal conditions in companion animals. |
| Royal Canin U.S. | Apr-24 | The company expanded its veterinary gastrointestinal (GI) nutrition portfolio with five new specialized diets for cats and dogs. These formulas, including hydrolyzed protein and low-fat options, are designed to support long-term digestive health and manage food-responsive sensitivities that often contribute to gastroesophageal reflux. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Animal Gastroesophageal Reflux Disease Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Drug Class | Proton Pump Inhibitors, H2-Receptor Antagonists, Prokinetic Agents, Antacids & Mucosal Protectants |
| Disease Severity | Mild, Moderate, Severe |
| Veterinary Practice Setting | General Veterinary Practices, Specialty Veterinary Hospitals, Veterinary Teaching & Research Institutions |
Animal Gastroesophageal Reflux Disease Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Veterinary Treatment Pathway Assessment |
|
| Companion Animal Owner Adoption and Compliance Analysis |
|
| White Space Opportunity Assessment by Animal Species |
|
Need a different cut of the data?
Request Custom ResearchWhat is the current size of the animal gastroesophageal reflux disease market?
What is the projected value of the animal gastroesophageal reflux disease industry by 2036?
How is rising prevalence of obesity and related conditions in pets driving demand in the animal GERD market?
How are diagnostic advancements and pet healthcare spending trends influencing GERD treatment adoption?
Why does the OTC segment lead the animal gastroesophageal reflux disease market?
Why is oral administration the fastest-growing route in the animal gastroesophageal reflux disease market?
Why does North America lead the animal gastroesophageal reflux disease market?
What factors are driving growth in the Asia Pacific animal gastroesophageal reflux disease market?
Who are the leading players in the animal gastroesophageal reflux disease landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization